RÉSUMÉ
The complement system is a complex, tightly regulated protein cascade involved in pathogen defense and the pathogenesis of several diseases. Thus, the development of complement modulators has risen as a potential treatment for complement-driven inflammatory pathologies. The enzymatically inactive MAP-2 has been reported to inhibit the lectin pathway by competing with its homologous serine protease MASP-2. The membrane-bound complement inhibitor CD55 acts on the C3/C5 convertase level. Here, we fused MAP-2 to the four N-terminal domains of CD55 generating a targeted chimeric inhibitor to modulate complement activation at two different levels of the complement cascade. Its biological properties were compared in vitro with the parent molecules. While MAP-2 and CD55 alone showed a minor inhibition of the three complement pathways when co-incubated with serum (IC50MAP-2+CD55 1-4 = 60.98, 36.10, and 97.01 nM on the classical, lectin, and alternative pathways, respectively), MAP-2:CD551-4 demonstrated a potent inhibitory activity (IC50MAP-2:CD55 1-4 = 2.94, 1.76, and 12.86 nM, respectively). This inhibitory activity was substantially enhanced when pre-complexes were formed with the lectin pathway recognition molecule mannose-binding lectin (IC50MAP-2:CD55 1-4 = 0.14 nM). MAP-2:CD551-4 was also effective at protecting sensitized sheep erythrocytes in a classical hemolytic assay (CH50 = 13.35 nM). Finally, the chimeric inhibitor reduced neutrophil activation in full blood after stimulation with Aspergillus fumigatus conidia, as well as phagocytosis of conidia by isolated activated neutrophils. Our results demonstrate that MAP-2:CD551-4 is a potent complement inhibitor reinforcing the idea that engineered fusion proteins are a promising design strategy for identifying and developing drug candidates to treat complement-mediated diseases.
Sujet(s)
Activation du complément , Protéines du système du complément , Animaux , Ovis , Antigènes CD55/pharmacologie , Lectines/métabolisme , Facteurs de transcription , Inhibiteurs du complément , Mannose-Binding Protein-Associated Serine Proteases/métabolismeRÉSUMÉ
Tyrosine kinase inhibitor (TKI) therapy is gaining attraction in advanced cancer therapeutics due to the ubiquity of kinases in cell survival and differentiation. Great progress was made in the past years in identifying tyrosine kinases that can function as valuable molecular targets and for the entrapment of their corresponding inhibitors in delivery compounds for triggered release. Herein we present a class of drug-delivery nanocompounds based on TKI Midostaurin-loaded gold nanoparticles that have the potential to be used as theranostic agents for the targeting of the FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia. We optimized the nanocompounds' formulation with loading efficiency in the 84-94% range and studied the drug release behavior in the presence of stimuli-responsive polymers. The therapeutic activity of MDS-loaded particles, superior to that of the free drug, was confirmed with toxicities depending on specific dosage ranges. No effect was observed on FLT3-negative cells or for the unloaded particles. Beyond druggability, we can track this type of nanocarrier inside biological structures as demonstrated via dark field microscopy. These properties might contribute to the facilitation of personalized drug dosage administration, critical for attaining a maximal therapeutic effect.
RÉSUMÉ
Osteoclasts are multinucleated cells of hematopoietic origin which are critically involved in physiological and pathological bone resorption. They develop from myeloid progenitors through characteristic gene expression changes and intercellular fusion. This process is directed by M-CSF and RANKL which are also able to trigger osteoclast development from bone marrow cells in vitro. Osteoclasts are conventionally visualized by histochemical staining followed by manual counting, which hinders kinetic studies and automated quantification. Here we describe two fluorescence-based assays for the real-time analysis of myeloid cell to osteoclast development (FRAMCO) in primary mouse bone marrow cell cultures. Both assays rely on red-to-green fluorescence conversion of the membrane-targeted tdTomato/membrane-targeted eGFP (mTmG) transgene by Cre recombinase driven by the osteoclast-specific cathepsin K promoter (Ctsk-Cre). In the first assay (FRAMCO1.1), osteoclast-specific gene expression triggers red-to-green color conversion of cells carrying both the Ctsk-Cre and mTmG transgenes. In the second assay (FRAMCO1.2), red-to-green fluorescence conversion is triggered by fusion of neighboring co-cultured bone marrow cells separately carrying either the Ctsk-Cre or the mTmG transgenes. The two assays were tested using a high-content confocal fluorescence imaging system, followed by automated quantification. The FRAMCO1.1 assay showed robust red-to-green fluorescence conversion of more than 50% of the culture (including mononuclear cells) within 3 days under osteoclastogenic conditions. The FRAMCO1.2 assay showed a less robust but still readily measurable red-to-green color conversion in multinuclear cells within 5 days of differentiation. The assays required both the Ctsk-Cre and the mTmG transgenes and gave no signals in parallel macrophage cultures. The proper functioning of the two assays was also confirmed at the DNA, mRNA and bulk protein level. The assay systems were validated using lisophosphatidylcholine, a previously reported inhibitor of preosteoclast fusion. Taken together, our assays allow high-throughput automated real-time analysis of two critical aspects of osteoclast development, facilitating the screening for novel drug candidates for the pharmacological control of osteoclast-mediated bone resorption.
RÉSUMÉ
Herein, we report the fabrication of a nanotherapeutic platform integrating near-infrared (NIR) imaging with combined therapeutic potential through photodynamic (PDT) and photothermal therapies (PTT) and recognition functionality against ovarian cancer. Owing to its NIR fluorescence, singlet oxygen generation and heating capacity, IR780 iodide is exploited to construct a multifunctional nanosystem for single-wavelength NIR laser imaging-assisted dual-modal phototherapy. We opted for loading IR780 into polymeric Pluronic-F127-chitosan nanoformulation in order to overcome its hydrophobicity and toxicity and to allow functionalization with folic acid. The obtained nanocapsules show temperature-dependent swelling and spectroscopic behavior with favorable size distribution for cellular uptake at physiological temperatures, improved fluorescence properties and good stability. The fabricated nanocapsules can efficiently generate singlet oxygen in solution and are able to produce considerable temperature increase (46⯰C) upon NIR laser irradiation. Viability assays on NIH-OVCAR-3 cells confirm the successful biocompatibilization of IR780 by encapsulating in Pluronic and chitosan polymers. NIR fluorescence imaging assays reveal the ability of folic-acid functionalized nanocapsules to serve as intracellular contrast agents and demonstrate their active targeting capacity against folate receptor expressing ovarian cancer cells (NIH-OVCAR-3). Consequently, the targeted nanocapsules show improved NIR laser induced phototherapeutic performance against NIH-OVCAR-3 cells compared to free IR780. We anticipate that this class of nanocapsules holds great promise as theranostic agents for application in image-guided dual PDT-PTT and imaging assisted surgery of ovarian cancer.
Sujet(s)
Chitosane , Hyperthermie provoquée , Nanocapsules , Tumeurs de l'ovaire , Photothérapie dynamique , Apoptose , Lignée cellulaire tumorale , Chitosane/analogues et dérivés , Femelle , Acide folique , Humains , Indoles , Imagerie optique , Tumeurs de l'ovaire/imagerie diagnostique , Tumeurs de l'ovaire/traitement médicamenteux , PhotothérapieRÉSUMÉ
Human C-reactive protein (CRP), an early clinical indicator of infectious or inflammatory conditions has been recently identified as a key biomarker associated with the development of COVID-19. The rapid and accurate determination of CRP level in blood serum is an urgent need to predict timely the risk of disease worsening. The emergence of nanotechnological tools has provided an attractive perspective in designing portable bioanalytical assays with fast response time, high sensitivity and specificity, and multiplexing capability for accurate, on-site disease diagnosis and monitoring. Due to their versatile optical properties, plasmonic nanoparticles (PNPs) are appealing candidates for biosensing applications. This review summarizes the advances in the application of PNPs for CRP detection and quantification. Particularly, we review the improvements attained in the detection of CRP using aggregation-based colorimetric, localized surface plasmon resonance (LSPR), plasmon-assisted fluorescence and chemiluminescence, and surface-enhanced Raman scattering (SERS) spectroscopic methods.
RÉSUMÉ
This paper presents the fabrication and characterization of new gold-silver core-shell nanoparticles labeled with para-mercaptobenzoic acid (4MBA) molecules and demonstrates their use as surface-enhanced Raman spectroscopy (SERS)-nanotags with ultra-bright traceability inside cells and ability to convey spectrally-coded information about the intracellular pH by means of SERS. Unlike previous reported studies, our fabrication procedure includes in the first step the synthesis of chitosan-coated gold nanoparticles as a seed material with subsequent growing of a silver shell. The bimetallic core-shell structure is revealed by transmission electron microscopy, high-angle annular dark field scanning transmission electron microscopy, energy-dispersive x-ray elemental mapping and the presence of two interacting localized surface plasmon resonance modes in UV-vis extinction spectrum. The high SERS activity and sensitivity of as fabricated 4MBA-chit-Au-AgNPs nano-constructs to different pH in solution is investigated under 532 and 633 nm laser lines excitation. Next, in view of future studies in cancer diagnosis, the in vitro antiproliferative effects of SERS-nanotags against human ovarian adenocarcinoma cells (NIH:OVCAR-3) are evaluated. The capacity to operate as bright SERS nanotags with precise localization at a single cell level as well as intracellular pH indicators is clearly demonstrated by performing cell imaging under scanning confocal Raman microscopy.
Sujet(s)
Or/composition chimique , Nanoparticules métalliques/composition chimique , Tumeurs de l'ovaire/diagnostic , Argent/composition chimique , Analyse spectrale Raman/méthodes , Benzoates/composition chimique , Lignée cellulaire tumorale , Femelle , Humains , Concentration en ions d'hydrogène , Tumeurs de l'ovaire/composition chimique , Thiols/composition chimiqueRÉSUMÉ
PURPOSE: Glioblastoma is a rapidly evolving lethal disease mainly due to its highly chemo- and radioresistant glioblastoma stem cells (GSCs). Herein, we tested if chitosan-capped gold nanoparticles (Chit-GNPs) may overcome the limitations of drug concentrations by increased cell internalization in GSCs and if such GNPs could enhance the response to irradiation. METHODS: Chitosan was used for Chit-GNP synthesis as a reducing and stabilizing agent. Chit-GNPs were characterized by spectroscopy, dark field, transmission electron microscopy and zeta potential measurements. Patient-derived GSCs and human osteoblasts were treated with increasing concentrations of nanoparticles and irradiated. The uptake and cytotoxicity of Chit-GNPs were compared to that of uncoated GNPs. RESULTS: The positively-charged, 26 nm-sized, spherical Chit-GNPs, showed a huge intracellular accumulation into the cytosol, lysosomes and near the nucleus, whereas no uncoated GNPs were internalized within GSCs. Surprisingly, Chit-GNPs were highly cytotoxic for GSCs irrespective of cell irradiation, that failed to add an additional benefit when combined with Chit-GNPs/GNPs. Moreover, Chit-GNPs were selectively cytotoxic for GSCs and did not affect the normal cells, despite an increased nanoparticle internalization. CONCLUSIONS: The important Chit-GNP internalization and their selective cytotoxicity for GSCs make this compound a potential novel anticancer agent and a promising backbone for drug delivery in glioblastoma.
Sujet(s)
Chitosane/administration et posologie , Glioblastome/traitement médicamenteux , Or/administration et posologie , Nanoparticules métalliques/administration et posologie , Cellules souches/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Systèmes de délivrance de médicaments/méthodes , HumainsRÉSUMÉ
Due to the good transparency of the human tissue in the biological spectral window, near-infrared (NIR)-dye loaded nanosystems enable more effective light-activated therapy and better contrast imaging with major impact on nanomedicine. Herein, we prepare Pluronic coated gold nanoparticles incorporating the hydrophobic NIR dye, IR780 iodide (GNP-Plu-IR780) to provide water-solubility and stability and demonstrate the proficiency of combining photodynamic and photothermal therapeutic activity with surface-enhanced resonance Raman scattering (SERRS) imaging facility. The potential of GNP-Plu-IR780 to operate as NIR-activatable agents was first assessed in aqueous solution by singlet oxygen generation measurements and monitoring the temperature increase of the nanoparticles. Subsequent in vitro uptake studies by dark field and differential interference contrast (DIC) microscopy reveal massive internalization of GNP-Plu-IR780 by murine colon carcinoma cells (C-26). Moreover, by exploiting the SERRS effect under 785â¯nm laser excitation we were able to perform intracellular tracking of GNP-Plu-IR780. Finally, NIR irradiation experiments conducted in vitro against C-26 cells show efficient phototherapeutic activity induced by GNP-Plu-IR780 with no dark cytotoxicity. Moreover, when compared to the administration of free drug or non-loaded GNP-Plu, the higher phototherapeutic activity of GNP-Plu-IR780 indicates the occurrence of cooperative synergistic effects by simultaneous photodynamic and photothermal activity.
Sujet(s)
Or/composition chimique , Indoles/composition chimique , Nanoparticules métalliques/composition chimique , Photothérapie dynamique/méthodes , Analyse spectrale Raman/méthodes , Animaux , Lignée cellulaire tumorale , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des radiations , Agents colorants/administration et posologie , Agents colorants/composition chimique , Produits de contraste/composition chimique , Interactions hydrophobes et hydrophiles , Indoles/administration et posologie , Rayons infrarouges , Souris , Taille de particule , Poloxamère/composition chimique , Oxygène singulet/métabolisme , Propriétés de surface , Nanomédecine théranostiqueRÉSUMÉ
Ovarian cancer is a common cause of cancer death in women and is associated with the highest mortality rates of all gynecological malignancies. Carboplatin (CBP) is the most used cytotoxic agent in the treatment of ovarian cancer. Herein, we design and assess a CBP nanotherapeutic delivery system which allows combinatorial functionalities of chemotherapy, pH sensing, and multimodal traceable properties inside live NIH:OVCAR-3 ovarian cancer cells. In our design, a pH-sensitive Raman reporter, 4-mercaptobenzoic acid (4MBA) is anchored onto the surface of chitosan-coated silver nanotriangles (chit-AgNTs) to generate a robust surface-enhanced Raman scattering (SERS) traceable system. To endow this nanoplatform with chemotherapeutic abilities, CBP is then loaded to 4MBA-labeled chit-AgNTs (4MBA-chit-AgNTs) core under alkaline conditions. The uptake and tracking potential of CBP-4MBA-chit-AgNTs at different Z-depths inside live ovarian cancer cells is evaluated by dark-field and differential interference contrast (DIC) microscopy. The ability of CBP-4MBA-chit-AgNTs to operate as near-infrared (NIR)-responsive contrast agents is validated using two noninvasive techniques: two-photon (TP)-excited fluorescence lifetime imaging microscopy (FLIM) and confocal Raman microscopy (CRM). The most informative data about the precise localization of nanocarriers inside cells correlated with intracellular pH sensing is provided by multivariate analysis of Raman spectra collected by scanning CRM. The in vitro cell proliferation assay clearly shows the effectiveness of the prepared nanocarriers in inhibiting the growth of NIH:OVCAR-3 cancer cells. We anticipate that this class of nanocarriers holds great promise for application in image-guided ovarian cancer chemotherapy.
Sujet(s)
Nanostructures , Carboplatine , Lignée cellulaire tumorale , Chitosane , Femelle , Humains , Concentration en ions d'hydrogène , Tumeurs de l'ovaire , Argent , Analyse spectrale RamanRÉSUMÉ
In this Research Article, we propose a new class of contrast agents for the detection and multimodal imaging of CD19(+) cancer lymphoblasts. The agents are based on NIR responsive hollow gold-silver nanospheres conjugated with antiCD19 monoclonal antibodies and marked with Nile Blue (NB) SERS active molecules (HNS-NB-PEG-antiCD19). Proof of concept experiments on specificity of the complex for the investigated cells was achieved by transmission electron microscopy (TEM). The microspectroscopic investigations via dark field (DF), surface-enhanced Raman spectroscopy (SERS), and two-photon excited fluorescence lifetime imaging microscopy (TPE-FLIM) corroborate with TEM and demonstrate successful and preferential internalization of the antibody-nanocomplex. The combination of the microspectroscopic techniques enables contrast and sensitivity that competes with more invasive and time demanding cell imaging modalities, while depth sectioning images provide real time localization of the nanoparticles in the whole cytoplasm at the entire depth of the cells. Our findings prove that HNS-NB-PEG-antiCD19 represent a promising type of new contrast agents with great possibility of being detected by multiple, non invasive, rapid and accessible microspectroscopic techniques and real applicability for specific targeting of CD19(+) cancer cells. Such versatile nanocomplexes combine in one single platform the detection and imaging of cancer lymphoblasts by DF, SERS, and TPE-FLIM microspectroscopy.
Sujet(s)
Nanoparticules métalliques , Lignée cellulaire tumorale , Or , Humains , Nanosphères , Argent , Analyse spectrale RamanRÉSUMÉ
The bioactive glasses doped with gold nanoparticles (AuNPs) are very attractive materials due to their potential in medical applications. In the present study Pluronic-nanogold hybrid nanoparticles were introduced during the sol-gel route of the SiO2-CaO-P2O5 glasses preparation. The obtained samples were characterized by UV-vis spectroscopy, X-ray diffraction, FT-IR spectroscopy, transmission electron and scanning electron microscopy and afterwards they were investigated in terms of bioactivity, protein adsorption and cells viability. The in vitro bioactivity assessment shows the increase of the number of agglomerated spherical shapes of apatite layers for all Au containing samples, but apatite like structure sizes are influenced by the AuNP content. Beside the spherical shapes, three-dimensional flower-like nanostructures were observed on the surface of the glass with 0.2mol% Au2O. Zeta potential and fluorescence spectroscopy measurements evidenced that the amount of serum albumin adsorbed onto the composites surface increases with the AuNP content. FT-IR measurements point out that the secondary structure of the adsorbed proteins presents few minor changes, indicating biocompatibility of the AuNP doped glasses. The good proliferation rate of Human keratinocytes cells obtained in the presence of samples with 0.15 and 0.2mol% Au2O is comparable with the values achieved from free AuNP, fact that proves the preservation of AuNP properties after their incorporation inside the bioactive glass matrices.
Sujet(s)
Nanoparticules métalliques , Apatites , Verre , Or , Humains , Silice , Spectroscopie infrarouge à transformée de Fourier , Diffraction des rayons XRÉSUMÉ
Acute lymphoblastic leukemia (ALL) is the malignancy with the highest incidence amongst children (26% of all cancer cases), being surpassed only by the cancers of the brain and of the nervous system. The most recent research on ALL is focusing on new molecular therapies, like targeting specific biological structures in key points in the cell cycle, or using selective inhibitors for transmembranary proteins involved in cell signalling, and even aiming cell surface receptors with specifically designed antibodies for active targeting. Nanomedicine approaches, especially by the use of nanoparticle-based compounds for the delivery of drugs, cancer diagnosis or therapeutics may represent new and modern ways in the near future anti-cancer therapies. This review offers an overview on the recent role of nanomedicine in the detection and treatment of acute lymphoblastic leukemia as resulting from a thorough literature survey. A short introduction on the basics of ALL is presented followed by the description of the conventional methods used in the ALL detection and treatment. We follow our discussion by introducing some of the general nano-strategies used for cancer detection and treatment. The detailed role of organic and inorganic nanoparticles in ALL applications is further presented, with a special focus on gold nanoparticle-based nanocarriers of antileukemic drugs.